Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page


Renal lnfarction Following Initiation of Fingolimod

Amal O. Alotaibi, Ghada A. Alsowailmi, Sara I. Alshahwan, Afnan A. Alsahli and Yaser M. Almalik

Fingolimod is the rst oral agent approved for the management of relapsing reming mulple sclerosis (RRMS). It was shown to reduce the progression and relapse rate of neurological disability by 30% and 54%, respecvely. Reported adverse eects of the drug include bradycardia, elevated liver enzymes, mild hypertension, and macular edema. No associaon between ngolimod and renal infarcon as an adverse eect has been presented to date. We report a case of a 45-year-old male paent with RRMS, who presented with renal infarcon and was treated with ngolimod